A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma

Luo, 2018, Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers, Int. J. Cancer, 143, 1696, 10.1002/ijc.31542 Xu, 2020, Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy, Mol. Ther. Oncolytics, 17, 241, 10.1016/j.omto.2020.03.021 Pitt, 2016, Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy, Ann. Oncol., 27, 1482, 10.1093/annonc/mdw168 Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat. Med., 19, 1423, 10.1038/nm.3394 Li, 2020, A signature of tumor immune microenvironment genes associated with the prognosis of nonsmall cell lung cancer, Oncol. Rep., 43, 795 Alsaab, 2017, PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome, Front. Pharmacol., 8, 561, 10.3389/fphar.2017.00561 Akinleye, 2019, Immune checkpoint inhibitors of PD-L1 as cancer therapeutics, J. Hematol. Oncol., 12, 92, 10.1186/s13045-019-0779-5 Zhang, 2019, Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade, RSC Adv., 9, 33903, 10.1039/C9RA04590B Wang, 2019, A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis, Cancer Cell Int., 19 Xie, 2019, A six-gene signature predicts survival of adenocarcinoma type of non-small-cell lung cancer patients: a comprehensive study based on integrated analysis and weighted gene coexpression network, Biomed. Res. Int., 2019, 10.1155/2019/4250613 Krzystanek, 2016, A robust prognostic gene expression signature for early stage lung adenocarcinoma, Biomark. Res., 4, 10.1186/s40364-016-0058-3 Ma, 2020, Identification of a sixteen-gene prognostic biomarker for lung adenocarcinoma using a machine learning method, J. Cancer, 11, 1288, 10.7150/jca.34585 Xu, 2020, A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma, Oncoimmunology, 9, 10.1080/2162402X.2020.1731943 Xu, 2020, Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma, Int. Immunopharmacol., 81, 10.1016/j.intimp.2019.105932 Wilkerson, 2010, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking, Bioinformatics, 26, 1572, 10.1093/bioinformatics/btq170 Yang, 2019, Molecular subtypes based on DNA methylation predict prognosis in colon adenocarcinoma patients, Aging, 11, 11880, 10.18632/aging.102492 Daily, 2017, Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives, Sci. Data, 4, 10.1038/sdata.2017.30 Yoshihara, 2013, Inferring tumour purity and stromal and immune cell admixture from expression data, Nat. Commun., 4, 10.1038/ncomms3612 Zhou, 2019, Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer, Cancer Immunol. Immunother., 68, 433, 10.1007/s00262-018-2289-7 Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, Omics, 16, 284, 10.1089/omi.2011.0118 Malta, 2018, Machine learning identifies stemness features associated with oncogenic dedifferentiation, Cell, 173, 338, 10.1016/j.cell.2018.03.034 Postow, 2015, Immune checkpoint blockade in cancer therapy, J. Clin. Oncol., 33, 1974, 10.1200/JCO.2014.59.4358 Lu, 2019, Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome, Neoplasia, 21, 591, 10.1016/j.neo.2019.04.003 Miranda, 2019, Cancer stemness, intratumoral heterogeneity, and immune response across cancers, Proc. Natl. Acad. Sci., 116, 9020, 10.1073/pnas.1818210116 Perez-Ramirez, 2016, Liquid biopsy in early stage lung cancer, J. Thorac. Dis., 5, 517 Mony, 2018, Prognostic implications of heterogeneity in intra-tumoral immune composition for recurrence in early stage lung cancer, Front. Immunol., 9, 2298, 10.3389/fimmu.2018.02298 Liu, 2017, The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer, Biomed. Pharmacother., 95, 55, 10.1016/j.biopha.2017.08.003 Pagès, 2005, Effector memory T cells, early metastasis, and survival in colorectal cancer, N. Engl. J. Med., 353, 2654, 10.1056/NEJMoa051424 Liu, 2020, Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer, Int. Immunopharmacol., 86, 10.1016/j.intimp.2020.106735 Shukuya, 2016, Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer, J. Thorac. Oncol., 11, 976, 10.1016/j.jtho.2016.02.015 Chen, 2015, Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future, J. Clin. Invest., 125, 3384, 10.1172/JCI80011 Long, 2019, Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma, EBioMedicine, 42, 363, 10.1016/j.ebiom.2019.03.022 Jiang, 2018, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nat. Med., 24, 1550, 10.1038/s41591-018-0136-1 Wang, 2020, Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy, Aging, 12, 3312, 10.18632/aging.102814 Zheng, 2020, Interaction between CAF and CD8+ T cells in non-small cell lung cancer affects prognosis and efficacy of immunotherapy, J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.9536 Chen, 2020, Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: evidence for immune checkpoint inhibitor therapy, Oncol. Lett., 20, 517, 10.3892/ol.2020.11605 Pérez-Guijarro, 2019, Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy, bioRxiv, 26, 781